| 1.92 -0.1 (-4.95%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.93  |
1-year : | 3.39 |
| Resists | First : | 2.51 |
Second : | 2.91 |
| Pivot price | 2.26 |
|||
| Supports | First : | 1.87 |
Second : | 1.55 |
| MAs | MA(5) : | 2.03 |
MA(20) : | 2.37 |
| MA(100) : | 3.2 |
MA(250) : | 2.4  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 4.3 |
D(3) : | 5 |
| RSI | RSI(14): 29.3 |
|||
| 52-week | High : | 4.17 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ESPR ] has closed above bottom band by 14.0%. Bollinger Bands are 15.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.03 - 2.05 | 2.05 - 2.06 |
| Low: | 1.83 - 1.85 | 1.85 - 1.87 |
| Close: | 1.88 - 1.91 | 1.91 - 1.93 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Thu, 16 Apr 2026
Esperion Therapeutics, Inc. ($ESPR) President and CEO 2025 Pay Revealed - Quiver Quantitative
Thu, 16 Apr 2026
[ARS] Esperion Therapeutics, Inc. SEC Filing - Stock Titan
Thu, 16 Apr 2026
Esperion (NASDAQ: ESPR) seeks 7M more shares for 2022 stock incentive plan - Stock Titan
Thu, 16 Apr 2026
Esperion Therapeutics soars amid vague takeover speculation - MSN
Thu, 02 Apr 2026
Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy - TradingView
Thu, 02 Apr 2026
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund. - Bitget
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 257 (M) |
| Shares Float | 255 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 60.9 (%) |
| Shares Short | 33,130 (K) |
| Shares Short P.Month | 33,530 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.24 |
| Profit Margin | -5.7 % |
| Operating Margin | 50.5 % |
| Return on Assets (ttm) | 9.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 143.6 % |
| Gross Profit (p.s.) | 0.87 |
| Sales Per Share | 1.56 |
| EBITDA (p.s.) | 0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -17.37 |
| PEG Ratio | 0 |
| Price to Book value | -1.56 |
| Price to Sales | 1.21 |
| Price to Cash Flow | -37.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|